A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• The actin cytoskeleton is crucial for cancer cell function but difficult to target due to toxicity.
• Tropomyosin isoforms are upregulated in cancers and can be targeted to disrupt actin filaments.

Purpose of the Study:

• To develop and evaluate novel anti-tropomyosin compounds for cancer therapy.
• To assess the efficacy and safety of TR100 in preclinical cancer models.

Main Methods:

• Development of a novel class of anti-tropomyosin compounds.
• In vitro and in vivo testing of lead compound TR100 in neuroblastoma and melanoma models.
• Evaluation of TR100's impact on tumor cell motility, viability, and cardiac function.

Main Results:

• Novel anti-tropomyosin compounds selectively disrupt cancer cell actin cytoskeleton.
• TR100 demonstrated efficacy in reducing tumor growth in neuroblastoma and melanoma models.
• TR100 exhibited no adverse effects on cardiac structure and function.

Conclusions:

• Targeting cancer-specific tropomyosin isoforms offers a strategy for selective actin cytoskeleton disruption.
• TR100 represents a promising novel anti-cancer agent with a favorable safety profile.
• This approach provides a pathway for developing new anti-actin therapies for various cancers.